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Ajay M. Shah, MD,a Douglas L. Mann, MD, FACCbB ritain’s popular vote to leave the EuropeanUnion (EU), termed Brexit, could cause majordisruptions for science and health care not
only in the United Kingdom, but also in mainland
Europe and the United States if appropriate steps to
mitigate this risk are not taken. Although a number
of op-ed papers have been written recently in leading
medical and scientiﬁc journals on the potential effect
of Brexit on science, the pharmaceutical industry,
and health care, none of these papers have discussed
the potential ramiﬁcations for cardiovascular transla-
tional medicine. Given that translational science
requires effective cooperation between basic and
clinical investigators in academia and industry,
patients and their families, patient advocacy groups,
and governmental funding and regulatory agencies
to evaluate and develop new therapies, the global
translational “eco-system” is inherently fragile and
is therefore extremely vulnerable to economic and/
or political turbulence. Here, we highlight several of
the potential consequences of Brexit on cardiovascu-
lar translational medicine.
We believe that there are 3 potential negative
consequences of Brexit with respect to cardiovascular
translational medicine. The ﬁrst and most obvious
concern is that any ﬁnancial turmoil in the United
Kingdom’s economy, along with a reduction in Eu-
ropean and industrial research funding streams, may
result in decreased funding for U.K. scientists. This is
particularly important for translational research,
which is traditionally slow and fraught with risk, but
where the United Kingdom has a strong track record.
If the inherent difﬁculties in conducting translational
research become compounded by an unstableFrom aKing’s College London British Heart Foundation Centre of Excel-
lence, London, United Kingdom; and the bWashington University School
of Medicine, St. Louis, Missouri.funding climate, it may entice U.K. investigators to
pursue other, more stable lines of investigation
and/or funding. Further, it may dissuade trainees
from pursuing basic and/or translational science in
U.K. laboratories. One of the painful lessons learned
in the United States from the effect of “sequestration”
on the National Institutes of Health budget, is that
turning the ﬁscal faucet back on after a period of
diminished funding does not wash away the unto-
ward consequences of closed laboratories and/or a
shrunken/dispirited scientiﬁc work force. Any insta-
bility in funding for research has long-term conse-
quences for science that often cannot easily be
repaired, which means that progress for new thera-
pies for patients with cardiovascular disease may be
slowed, halted, or never initiated.
A second potential problem created by Brexit is the
negative effect on the conduct of multinational phase
II and III clinical trials and the approval process for
new products. As noted by Steve Bates, CEO of the
BioIndustry Association, a British life sciences trade
organization, “The future structure of medicine
regulation in Europe is now thrown into question” (1).
The EU Clinical Trials Regulation, although not
necessarily perfect, has the great advantage of
establishing a common framework for clinical trials
and harmonizing procedures within the EU, thereby
signiﬁcantly reducing the administrative burden for
setting up and running multinational trials. If the
United Kingdom is not within this system, then the
regulation of clinical trials in Europe will require
separate clinical trial authorization procedures,
which will add unnecessary cost to the already
expensive process of developing new therapies.
Brexit may also add to the complexity of approving
new therapies. As will be discussed in a forthcoming
issue of JACC: Basic to Translational Science, the
process for obtaining post-market approval differs
vastly in the United States and Europe (2). Europe
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417currently offers the following 4 different routes for
obtaining marketing authorization for drugs: 1) a
“Centralized Process” controlled through the Euro-
pean Medicines Agency (EMA) single license valid in
all EU member states and mandatory for certain
classes of drugs (treatment of human immunodeﬁ-
ciency virus/acquired immunodeﬁciency syndrome,
oncology drugs); 2) a “Decentralized Procedure” in
which manufacturers can apply for simultaneous
approval in more than 1 EU state for products that
have not yet been authorized in any EU state and do
not fall under the mandatory centralized process; 3) a
“National Process” in which each EU state can have
its own procedures for approving drugs that fall
outside of those required to undergo the centralized
process; and 4) the process of “Mutual Recognition”
in which drugs approved in 1 EU state via that state’s
national process can obtain marketing authorization
in another EU member state. If the United Kingdom is
not within EU, then a separate national authorization
would need to be obtained and the centralized pro-
cedure and/or mutual recognition process would not
be applicable to reduce the administrative burden of
applications in the EU and United Kingdom. Contrary
to the common notion that Food and Drug Adminis-
tration processes are signiﬁcantly slower than those
of the EMA, the median times for full protocol
reviews are w20% longer for the EMA compared with
the Food and Drug Administration (3). Adding
complexity that slows the approval process is bad for
patients, and it adds costs rather than revenues for
the sponsors that develop their products in Europe,
which is bad for the economic engine that drives new
innovations.
A third effect of Brexit on cardiovascular trans-
lational medicine is how it may inﬂuence the vitalityof the research enterprise and the “spirit of science,”
both in and outside of the United Kingdom. To quote
Sir Paul Nurse, a former President of the Royal Society
and current Director of the Francis Crick Institute,
“Science thrives on the permeability of ideas and
people, and ﬂourishes in environments that pool
intelligence, minimize barriers and are open to free
exchange and collaboration” (4). British translational
research and medicine beneﬁts greatly from in-
teractions with talented scientists from across the EU
and elsewhere, many of whom also come and work in
the United Kingdom. The United Kingdom also has a
signiﬁcant effect on scientiﬁc policy decisions at the
EU level. To the extent that Brexit compromises this
synergistic enterprise, it has the potential to slow the
scientiﬁc development of novel new therapies to treat
patients with cardiovascular disease.
Much will depend upon the nature of the new
relationship that is agreed between the United
Kingdom and the EU. The potential risks and chal-
lenges previously discussed can be mitigated if sufﬁ-
cient priority is given to the maintenance and
strengthening of scientiﬁc relationships. Both political
will and new funding streams will likely be required.
Given that cardiovascular disease remains the number
1 cause of death worldwide, we do not view Brexit as a
United Kingdom or EU problem, we view it as a global
problem that affects all of us. As always, we welcome
your thoughts and would like to hear what you think
about the effect of Brexit on cardiovascular trans-
lational science, either through social media
(#JACCBTS) or by e-mail (jaccbts@acc.org).
ADDRESS CORRESPONDENCE TO: Dr. Douglas L.
Mann, Heart House, 2400 North Street NW, Wash-
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